Posted October 9, 2019: by Bill Sardi

    Vaccine Attempts To Prevent 70,000 Cases Of Brain Inflammation But Possibly Causes Hundreds Of Thousands Of Cases Of A Chronic Autoimmune Nerve Disorder

    Vaccines are safe and effective.  Check.

    The vaccine used to prevent Japanese encephalitis, a dreaded mosquito-borne viral infection that incapacitates children and adults throughout Asia, is without serious side effects.  Check.

    But what if this vaccine causes another disease other than encephalitis?  Maybe nobody would ever know.

    That is precisely what is going on in China.

    Researchers in China have made a disturbing connection between vaccination against viral-induced Japanese encephalitis (brain inflammation) and the onset of myasthenia gravis, a chronic autoimmune disease that results in progressive weakness of the muscles used for breathing and movement of arms and legs (motor neurons).

    The shocking report, published in the Annals of Neurology, September of 2018, has been ignored.

    According to the most recent review (2017), vaccines employed to prevent Japanese encephalitis (JE) are generally regarded as safe and effective.  The incidence of vaccine-induced encephalitis, always a potential threat for any vaccine, has not been found to result from either of the two types of vaccines used to inoculate against Japanese encephalitis.

    But now this shocking discovery.

    The vaccine industry is mum and a year after this was reported in a major medical journal, medical news reporters aren’t saying a word about it either, possibly not to provide fodder for the anti-vaccine movement that has erupted over the issue of mandatory vaccines in the U.S.

    Vaccination is persistently performed on millions of school children in Asia in an effort to prevent 70,000 cases of JE and another 20,000 JE-related deaths annually. The Japanese encephalitis vaccine attempts to prevent a mosquito-transmitted viral infection of the brain.

    Myasthenia gravis: an autoimmune attack on nerve cells

    Myasthenia gravis affects motor nerves that control muscles via release a chemical called acetylcholine.  There are acetylcholine receptors (doorways) on the surface of these nerve cells.  In myasthenia gravis antibodies attack acetylcholine receptors at junctions where nerve cells and muscles intersect.  Myasthenia gravis patients experience a variety of chronic symptoms including seizures, droopy eyelids, facial paralysis, fatigue, hoarse voice, difficulty swallowing and double vision.

    Investigation of vaccines in the development of myasthenia gravis (MG) drew the attention of investigators because vaccines have been reported to induce immune diseases, including MG.  Here is the compelling evidence:

    1. The proportion of childhood myasthenia gravis (MG prior to age 15) in a given population is reported to vary.  Fifty-percent (50%) of myasthenia gravis cases in China affect children but only 10-15% in other Asian countries.  (Neuroimmunology Neuroinflammation 1: 127-30, 2014) This caused researchers to delve further into this China MG phenomenon.

    2. The similarity of genetic factors in Asian countries rules out genetics as a reason for the high rate of childhood myasthenia in China.

    3. What investigators report is, among the 2,161 childhood myasthenia gravis patients, 38 subjects reported a history of inoculation before the onset, relapse, or exacerbation of MG symptoms.

    4. More importantly, greater than 40% of study patients with childhood MG presented with their first MG symptoms before they were 4 years of age, which coincides with the Chinese planned‐immunization program timetable.

      There are two choices of vaccines against MG: (1) Inactivated Japanese encephalitis vaccine or (2) live attenuated Japanese encephalitis vaccines are used.  For reasons of economy, only the live attenuated JE vaccine is used in China.

    5. There is a distinct calendar pattern of changes in acetylcholine receptor antibodies concentration which fits with the timing of live attenuated Japanese encephalitis vaccine (LA-JEV) immunization in Chinese children, suggesting a possible role for LA‐JEV vaccination in the production of acetylcholine receptor antibodies.

    6. After injection of various other vaccines: DTP (diphtheria/tetanus/pertussis-whooping cough); MMR (measles/mumps/Rubella); HPB (hepatitis B); and tuberculosis vaccine), only live-attenuated Japanese encephalitis vaccine (LA-JEV) was found to produce antibodies against acetylcholine cell receptors.

    7. To further confirm their findings in humans, mice injected with live‐attenuated Japanese encephalitis vaccine (LA‐JEV) developed features of myasthenia gravis.These findings suggest that LA‐JEV immunization triggers the clinical and pathophysiological changes characteristic of human MG when injected in mice.

    Two types of vaccine

    The exclusive use of live attenuated Japanese encephalitis vaccine in China may explain the propensity to develop this disease in childhood in China.  The live attenuated JE vaccine is largely used for reasons of cost and convenience.

    The live attenuated vaccine is reported to cost 75-cents per dose versus $5.00 US per dose for the inactivated vaccine that is used in many developed countries.  It is obviously far less expensive than the inactivated JE vaccine.  The live attenuated vaccine also requires only 1 dose to achieve immunity in ~95% of children.

    Given economic concerns, long‐term immunity, and a simpler immunization strategy, live attenuated Japanese encephalitis vaccine is widely used in China, India and throughout southeast Asia.

    The inactivated Japanese encephalitis vaccine in the U.S. has been reported to produce only 1% serious adverse events (0.3 serious per 100,000 doses) with no reports of nervous system disease.  The cost of JE vaccination is $292 per dose in the U.S., and two doses are recommended.

    Of the 67% of patients who survive JE, 32% are reported to recover completely and 68% deal with long-term symptoms.

    The live-attenuated Japanese encephalitis vaccine is listed on the World Health Organization catalog, giving it an image of presumed safety.

    For background reference, live attenuated viruses, which are weakened viruses, are used in vaccines for measles and chicken pox (Varicella).   Inactivated vaccines may not always induce an immune response (production of antibodies) and several doses may be required, as is the case with inactivated Japanese encephalitis vaccine.

    How many develop vaccine-associated myasthenia gravis?

    It is estimated that the annual incidence (occurrence) and prevalence (total infected) rates of myasthenia gravis are estimated to be 5.3 (range: 1.7-21.3 million) and 77.7/million (range: 15-179 million) respectively in China.

    Using lowest incidence numbers, among all 1.7 million cases of myasthenia gravis (incidence), if 50% were childhood cases as reported in China, that would represent 850,000 cases of childhood MG.  If 38 of every 2161 of these MG children developed MG from vaccination as reported in the recent study cited above, and all childhood MG cases were vaccinated, then a horrific 14,946 estimated cases of childhood MG would emanate from vaccination!  If the 21.3 million cases number is factored, an estimated 187,274 children would experience vaccine-induced myasthenia gravis!

    In rural parts of China, parental informed consent is not likely to take place.  Parents would have no clue as what caused the onset of myasthenia gravis.  Product inserts that accompany packaging of this viral vaccine do not mention myasthenia gravis.

    The current vaccine may not protect against an emerging strain

    There has also been another disturbing recent finding.  Both live attenuated and inactivated-Japanese encephalitis vaccines (JEV) are based on a particular strain of the virus (genotype 3 or G3).  A recent report shows, after inoculation with JE vaccines, the production of neutralizing antibodies against G3, G1 and G5 JEV in the serum samples were 100%, 96% and 35%, respectively.  Beginning in 2008 there has been an emergence of G5 genotype Japanese encephalitis, which would not confer immunity using the current vaccine.

    How myasthenia gravis initially develops (in the thymus gland, not the brain)

    What is intriguing is how myasthenia gravis develops after mosquito inoculation of the Japanese encephalitis virus.  The Epstein-Barr virus which is the offending agent in JE has been reported in the thymus gland of myasthenia gravis patients.

    Young subjects are especially vulnerable to infection because their thymus gland, which produces antibody-producing T-cells to facilitate immunity against viruses like Epstein-Barr, shrinks as children grow.

    To say it another way, “weaponized” (naive) T-cells that haven’t produced any antibodies yet and are thus prepared to produce antibodies (immunoglobulins) against any new incoming viruses like the Epstein-Barr virus, are in short supply as children grow.

    This shriveling of the thymus gland is linked to a shortage of zinc in the diets of children rather than an inevitable outcome of childhood growth.

    Aged adults are also vulnerable to encephalitis due to their weakened immune system.  It is reported that centenarians (live 100 years) exhibit intact immunity whereas other who do not live to age 100 do not.  Zinc supplementation has been reported to maintain active immunity against the Epstein-Barr virus via zinc supplementation among senior adults which would be a preventive or therapeutic remedy for any child or adult in regard to encephalitis.

    Various pharmacologic remedies to prevent or treat encephalitis have been proposed.  But preventive zinc supplementation would be economical and produce broader protection against all infectious disease.  Essentially, zinc is a “universal vaccine” that is ignored in modern medicine.  Zinc would also likely increase the effectiveness of vaccines by improving antibody response.

Comments are closed.